Page 5 - Binding Affinity News Today

In a new study, researchers performed an in vitro analysis to isolate ultralong bovine heavy chains that showed binding with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related coronaviruses (CoVs).

Researchers at the Paul Scherrer Institute PSI, in collaboration with ETH Zurich, have optimized a method for tumor diagnosis using radionuclides.

Scientists have identified lucidenic acid A, one of the bioactive compounds of Ganoderma lucidum, as a potential inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) host cell entry. The study has recently been published in the journal Food and Chemical Toxicology.

A recent study designed immunogens to induce antibodies against SARS-CoV-2 variants.

Researchers performed deep mutational scanning for the SARS-CoV-2 Omicron variant of concern sub-VOC BA.1 and BA.2 receptor-binding domains.

In a recent study posted to the bioRxiv* preprint server, researchers in Taiwan and the United States explore the resistance of a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-variant BA.4.6 to the therapeutic monoclonal antibodies currently being used to treat coronavirus disease 2019 (COVID-19).

Researchers demonstrated that advances in modeling protein-ligand interactions using machine learning-based approaches are needed to exploit AlphaFold2 for antibiotic discovery better.

In a new study, researchers assessed the effects of N501Y mutation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein on binding to angiotensin-converting enzyme-2 (ACE-2).

Researchers performed a structural bioinformatics analysis to evaluate the binding energy of the SARS-CoV-2 Omicron variants of concern spike protein receptor-binding domain to human angiotensin-converting enzyme 2 receptor compared to other VOCs.

Researchers investigated the potential anti-COVID-19 activity of traditional Chinese medicine.